Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 02, 2023	Apr. 03, 2022
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	$ 1,204
Provision/(credit)	[2]	(44)	$ 43
Utilization and other	[3]	(411)
Balance, ending	[4]	750
Other Current Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning		991
Balance, ending		548
Other Noncurrent Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning		213
Balance, ending		202
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	1,196
Provision/(credit)		(36)
Utilization and other	[3]	(420)
Balance, ending	[4]	740
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	0
Provision/(credit)		(10)
Utilization and other	[3]	10
Balance, ending	[4]	0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	8
Provision/(credit)		2
Utilization and other	[3]	(1)
Balance, ending	[4]	$ 9

[1] Included in Other current liabilities ($991 million) and Other noncurrent liabilities ($213 million).

[2] Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: credits of $28 million for the three months ended April 2, 2023 and credits of $4 million for the three months ended April 3, 2022.

[3] Includes adjustments for foreign currency translation.

[4] Included in Other current liabilities ($548 million) and Other noncurrent liabilities ($202 million).